KR102828343B1 - 오로라 a 선택적 억제제로서 유용한 신규 헤테로사이클릭 화합물 - Google Patents
오로라 a 선택적 억제제로서 유용한 신규 헤테로사이클릭 화합물 Download PDFInfo
- Publication number
- KR102828343B1 KR102828343B1 KR1020227021336A KR20227021336A KR102828343B1 KR 102828343 B1 KR102828343 B1 KR 102828343B1 KR 1020227021336 A KR1020227021336 A KR 1020227021336A KR 20227021336 A KR20227021336 A KR 20227021336A KR 102828343 B1 KR102828343 B1 KR 102828343B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- alkyl
- methyl
- membered
- heterocyclic ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/073786 | 2020-01-22 | ||
| CN2020073786 | 2020-01-22 | ||
| CNPCT/CN2020/076159 | 2020-02-21 | ||
| CN2020076159 | 2020-02-21 | ||
| CNPCT/CN2020/085922 | 2020-04-21 | ||
| CN2020085922 | 2020-04-21 | ||
| PCT/CN2021/073169 WO2021147974A1 (en) | 2020-01-22 | 2021-01-22 | Novel heterocyclic compounds useful as aurora a selective inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220131514A KR20220131514A (ko) | 2022-09-28 |
| KR102828343B1 true KR102828343B1 (ko) | 2025-07-04 |
Family
ID=76993163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227021336A Active KR102828343B1 (ko) | 2020-01-22 | 2021-01-22 | 오로라 a 선택적 억제제로서 유용한 신규 헤테로사이클릭 화합물 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230128198A1 (https=) |
| EP (1) | EP4093736A4 (https=) |
| JP (1) | JP7688646B2 (https=) |
| KR (1) | KR102828343B1 (https=) |
| CN (2) | CN114423751B (https=) |
| AU (1) | AU2021209744B2 (https=) |
| CL (1) | CL2022001951A1 (https=) |
| CO (1) | CO2022010878A2 (https=) |
| IL (1) | IL294247B2 (https=) |
| MX (1) | MX2022009059A (https=) |
| PH (1) | PH12022551858A1 (https=) |
| TW (1) | TWI785474B (https=) |
| WO (1) | WO2021147974A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CN112239465A (zh) | 2019-07-16 | 2021-01-19 | 微境生物医药科技(上海)有限公司 | 极光激酶抑制剂及其用途 |
| CN112898292A (zh) | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
| JP2025506772A (ja) * | 2022-02-23 | 2025-03-13 | リペア セラピューティクス インコーポレイテッド | ポロ様キナーゼ４（ｐｌｋ４）阻害剤、医薬組成物、ならびにそれらを調製する方法、及びそれらの使用方法 |
| CN115057811B (zh) * | 2022-05-26 | 2024-06-14 | 安庆朗坤药业有限公司 | 一种2-溴甲基-3,5-二氟吡啶的制备方法 |
| CN115322143B (zh) * | 2022-07-21 | 2023-07-14 | 安徽德诺医药股份有限公司 | 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法 |
| WO2024230647A1 (zh) * | 2023-05-05 | 2024-11-14 | 苏州信诺维医药科技股份有限公司 | 杂环类化合物、其药物组合物和其应用 |
| CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008081492A (ja) * | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| EP2254888B1 (en) * | 2008-02-22 | 2014-12-24 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
| TWI693218B (zh) * | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
| MX2021006011A (es) * | 2018-11-30 | 2021-09-21 | Lilly Co Eli | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. |
| CN112239465A (zh) * | 2019-07-16 | 2021-01-19 | 微境生物医药科技(上海)有限公司 | 极光激酶抑制剂及其用途 |
| CN112898292A (zh) * | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
-
2021
- 2021-01-21 TW TW110102296A patent/TWI785474B/zh active
- 2021-01-22 WO PCT/CN2021/073169 patent/WO2021147974A1/en not_active Ceased
- 2021-01-22 MX MX2022009059A patent/MX2022009059A/es unknown
- 2021-01-22 CN CN202180003823.8A patent/CN114423751B/zh active Active
- 2021-01-22 CN CN202310353468.8A patent/CN116354936A/zh active Pending
- 2021-01-22 JP JP2022544153A patent/JP7688646B2/ja active Active
- 2021-01-22 AU AU2021209744A patent/AU2021209744B2/en active Active
- 2021-01-22 PH PH1/2022/551858A patent/PH12022551858A1/en unknown
- 2021-01-22 IL IL294247A patent/IL294247B2/en unknown
- 2021-01-22 US US17/794,641 patent/US20230128198A1/en not_active Abandoned
- 2021-01-22 KR KR1020227021336A patent/KR102828343B1/ko active Active
- 2021-01-22 EP EP21743926.4A patent/EP4093736A4/en active Pending
- 2021-09-24 US US17/484,456 patent/US11384066B1/en active Active
-
2022
- 2022-07-19 CL CL2022001951A patent/CL2022001951A1/es unknown
- 2022-08-02 CO CONC2022/0010878A patent/CO2022010878A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114423751A (zh) | 2022-04-29 |
| JP2023513419A (ja) | 2023-03-31 |
| CO2022010878A2 (es) | 2022-08-19 |
| CA3161268A1 (en) | 2021-07-29 |
| CN116354936A (zh) | 2023-06-30 |
| IL294247A (en) | 2022-08-01 |
| US11384066B1 (en) | 2022-07-12 |
| KR20220131514A (ko) | 2022-09-28 |
| MX2022009059A (es) | 2022-08-15 |
| JP7688646B2 (ja) | 2025-06-04 |
| TW202140449A (zh) | 2021-11-01 |
| CL2022001951A1 (es) | 2023-04-14 |
| EP4093736A4 (en) | 2024-01-10 |
| WO2021147974A1 (en) | 2021-07-29 |
| IL294247B1 (en) | 2025-07-01 |
| IL294247B2 (en) | 2025-11-01 |
| US20230128198A1 (en) | 2023-04-27 |
| AU2021209744B2 (en) | 2023-08-31 |
| TWI785474B (zh) | 2022-12-01 |
| AU2021209744A1 (en) | 2022-07-07 |
| EP4093736A1 (en) | 2022-11-30 |
| PH12022551858A1 (en) | 2024-01-03 |
| CN114423751B (zh) | 2023-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102828343B1 (ko) | 오로라 a 선택적 억제제로서 유용한 신규 헤테로사이클릭 화합물 | |
| JP7644517B2 (ja) | Ｋｒａｓ突然変異型タンパク質阻害剤 | |
| JP7005582B2 (ja) | ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物 | |
| JP7644023B2 (ja) | ホスファチジルイノシトール３－キナーゼ阻害剤 | |
| CN104428299B (zh) | 5-氮杂吲唑化合物及其使用方法 | |
| KR101964251B1 (ko) | 약학적 화합물 | |
| CN112552295A (zh) | Kras突变蛋白抑制剂 | |
| JP2023509495A (ja) | ＲＯＲγｔ阻害剤、その製造方法及び使用 | |
| KR102609431B1 (ko) | Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체 | |
| EP3209652B1 (en) | Tricyclic atropisomer compounds | |
| AU2015335703A1 (en) | Carbazole derivatives | |
| WO2016150971A1 (en) | Aminoindazole derivatives as sodium channel inhibitors | |
| CN105541693B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
| CN112513041A (zh) | 三环化合物 | |
| JP7447020B2 (ja) | トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびｍＧｌｕ５受容体のモジュレータとしてのそれらの使用 | |
| CN119490450A (zh) | 一种含肟化合物及其用途 | |
| CN114671878B (zh) | 取代的含氮双环化合物及其用途 | |
| CN114671856A (zh) | 多取代的尿嘧啶衍生物及其用途 | |
| CA3161268C (en) | Heterocyclic compounds useful as aurora a selective inhibitors | |
| TW202136237A (zh) | RORγt抑制劑及其製備方法和用途 | |
| HK40066473B (en) | Novel heterocyclic compounds useful as aurora a selective inhibitors | |
| HK40066473A (zh) | 用作选择性aurora a抑制剂的新型杂环化合物 | |
| HK40084694A (en) | Azalactam compounds as hpk1 inhibitors | |
| HK40053093A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| HK1208439B (zh) | 5-氮杂吲唑化合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20220622 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220829 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20241119 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20250501 |
|
| PG1601 | Publication of registration | ||
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |